Weinberg A - Search Results

1

Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.

Oberst MD, Augé C, Morris C, Kentner S, Mulgrew K, McGlinchey K, Hair J, Hanabuchi S, Du Q, Damschroder M, Feng H, Eck S, Buss N, de Haan L, Pierce AJ, Park H, Sylwester A, Axthelm MK, Picker L, Morris NP, Weinberg A, Hammond SA. Oberst MD, et al. Among authors: weinberg a. Mol Cancer Ther. 2018 May;17(5):1024-1038. doi: 10.1158/1535-7163.MCT-17-0200. Epub 2018 Mar 15. Mol Cancer Ther. 2018. PMID: 29545330 Free PMC article.

2

OX40: targeted immunotherapy--implications for tempering autoimmunity and enhancing vaccines.

Weinberg AD. Weinberg AD. Trends Immunol. 2002 Feb;23(2):102-9. doi: 10.1016/s1471-4906(01)02127-5. Trends Immunol. 2002. PMID: 11929124 Review.

3

A signal through OX40 (CD134) allows anergic, autoreactive T cells to acquire effector cell functions.

Lathrop SK, Huddleston CA, Dullforce PA, Montfort MJ, Weinberg AD, Parker DC. Lathrop SK, et al. Among authors: weinberg ad. J Immunol. 2004 Jun 1;172(11):6735-43. doi: 10.4049/jimmunol.172.11.6735. J Immunol. 2004. PMID: 15153490

4

OX40 (CD134) engagement drives differentiation of CD4+ T cells to effector cells.

Huddleston CA, Weinberg AD, Parker DC. Huddleston CA, et al. Among authors: weinberg ad. Eur J Immunol. 2006 May;36(5):1093-103. doi: 10.1002/eji.200535637. Eur J Immunol. 2006. PMID: 16541471 Free article.

5

Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study.

Weinberg AD, Thalhofer C, Morris N, Walker JM, Seiss D, Wong S, Axthelm MK, Picker LJ, Urba WJ. Weinberg AD, et al. J Immunother. 2006 Nov-Dec;29(6):575-85. doi: 10.1097/01.cji.0000211319.00031.fc. J Immunother. 2006. PMID: 17063120

6

Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses.

Ruby CE, Redmond WL, Haley D, Weinberg AD. Ruby CE, et al. Eur J Immunol. 2007 Jan;37(1):157-66. doi: 10.1002/eji.200636428. Eur J Immunol. 2007. PMID: 17183611 Free article.

7

Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain.

Morris NP, Peters C, Montler R, Hu HM, Curti BD, Urba WJ, Weinberg AD. Morris NP, et al. Mol Immunol. 2007 May;44(12):3112-21. doi: 10.1016/j.molimm.2007.02.004. Epub 2007 Mar 19. Mol Immunol. 2007. PMID: 17374396 Free PMC article.

8

Targeting OX40 and OX40L for the treatment of autoimmunity and cancer.

Redmond WL, Weinberg AD. Redmond WL, et al. Crit Rev Immunol. 2007;27(5):415-36. doi: 10.1615/critrevimmunol.v27.i5.20. Crit Rev Immunol. 2007. PMID: 18197805 Review.

9

OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor.

Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, Weinberg AD. Gough MJ, et al. Among authors: weinberg ad. Cancer Res. 2008 Jul 1;68(13):5206-15. doi: 10.1158/0008-5472.CAN-07-6484. Cancer Res. 2008. PMID: 18593921 Free article.

10

The effect of aging on OX40 agonist-mediated cancer immunotherapy.

Ruby CE, Weinberg AD. Ruby CE, et al. Cancer Immunol Immunother. 2009 Dec;58(12):1941-7. doi: 10.1007/s00262-009-0687-6. Epub 2009 Mar 14. Cancer Immunol Immunother. 2009. PMID: 19288101 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,495 results

Search Page